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Summary 28 
 29 
CBP/p300 are transcription co-activators whose binding is a signature of enhancers, cis-regulatory 30 
elements that control patterns of gene expression in multicellular organisms. Active enhancers 31 
produce bi-directional enhancer RNAs (eRNAs) and display CBP/p300 dependent histone 32 
acetylation. Here, we demonstrate that CBP binds directly to RNAs in vivo and in vitro. RNAs 33 
bound to CBP in vivo include a large number of eRNAs. Using steady-state histone 34 
acetyltransferase (HAT) assays we show that an RNA binding region in the HAT domain of CBP²35 
a regulatory motif unique to CBP/p300²allows RNA to stimulate CBP¶s HAT activity. At enhancers 36 
where CBP interacts with eRNAs, stimulation manifests in RNA-dependent changes in the histone 37 
acetylation mediated by CBP, such as H3K27ac, and by corresponding changes in gene 38 
expression. By interacting directly with CBP, eRNAs contribute to the unique chromatin structure at 39 
active enhancers, which in turn is required for regulation of target genes.   40 
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Introduction 41 
 42 
Enhancers confer spatiotemporal specificity to gene expression and orchestrate gene expression 43 
patterns in response to environmental and/or developmental stimuli (Lam et al., 2014). Enhancers 44 
account for the majority of transcription factor binding sites in the genome and have a 45 
characteristic chromatin structure. (Heinz et al., 2015). The number of potential enhancer elements 46 
greatly exceeds the number of coding regions, however most are maintained in a silent or poised 47 
state until an activating signal is received (Rada-Iglesias et al., 2011). Upon activation, binding of 48 
cell-type or temporal-specific transcription factors (TFs) to cognate DNA motifs recruits 49 
transcription co-activators, such as histone acetyltransferases CBP and p300 and RNA 50 
polymerase II (PolII) (Creyghton et al., 2010; Li et al., 2013). This results in two hallmarks of active 51 
enhancers: the production of bi-directional non-coding RNA transcripts known as enhancer RNAs 52 
(eRNAs) (Hah et al., 2011; Kim et al., 2010; Wang et al., 2011; ¯rom et al., 2010) and elevated 53 
histone 3 lysine 27 acetylation (H3K27ac) (Creyghton et al., 2010). 54 
 55 
Increasing evidence points to a direct role for eRNAs in enhancer function (Kim and Shiekhattar, 56 
2015). eRNAs regulate looping between enhancers and promoters through recruitment of cohesin 57 
(Hsieh et al., 2014; Li et al., 2013), increase chromatin accessibility (Mousavi et al., 2013), and aid 58 
the recruitment of mediator to promoters (Lai et al., 2013). Consistently, depletion of eRNAs affects 59 
transcription from enhancer-associated genes (Kim et al., 2010; Lai et al., 2013; Li et al., 2013; 60 
Melo et al., 2013; Mousavi et al., 2013). At poised genes, eRNAs promote release of paused PolII 61 
into the gene body (Schaukowitch et al., 2014).  62 
 63 
Several non-coding RNAs (ncRNAs) interact with chromatin-modifying enzymes and modulate 64 
enzymatic function (Cifuentes-Rojas et al., 2014; Di Ruscio et al., 2013; Kaneko et al., 2014a; 65 
2014b; 2013; Wongtrakoongate et al., 2015; Yang et al., 2014). Binding of RNA to Polycomb 66 
repressive complex 2 (PRC2) decreases its methyltransferase activity and recruitment to 67 
promoters (Beltran et al., 2016; Cifuentes-Rojas et al., 2014; Kaneko et al., 2013; 2014a; 2014b). 68 
ncRNA transcribed proximal to the C/EBPA locus interacts with DNA methyltransferase 1 (DNMT1) 69 
to block DNA methylation at the promoter (Di Ruscio et al., 2013). A key question is whether 70 
eRNAs play a similar role in modulating chromatin at enhancers. Indeed, eRNA transcripts do not 71 
direct methylation changes at enhancers upon activation, which result from active transcription by 72 
PolII (Kaikkonen et al., 2013). 73 
 74 
Elevated H3K27ac is another hallmark of active enhancers, produced by CBP and p300 (Jin et al., 75 
2011; Tie et al., 2009). CBP/p300 bind a vast array of TFs through transactivation domains 76 
(TADs), acting as a transcription network µKXE¶ (Bedford et al., 2010; Wang et al., 2013). The broad 77 
interactome results in nearly-universal recruitment of CBP and p300 to enhancers, such that 78 
CBP/p300 occupancy is a key feature (Creyghton et al., 2010) and identifies enhancers genome-79 
wide (May et al., 2012). The enzymatic activity of CBP and p300 is localized in their catalytic 80 
histone acetyltransferase (HAT) domain and targets both histones and numerous TF substrates, 81 
including p53 and PolII (Barlev et al., 2001; Jin et al., 2011; Schrder et al., 2013; Tie et al., 2009; 82 
Wang et al., 2008a). Acetylation of PolII by CBP promotes PolII release into the gene body 83 
(Schrder et al., 2013). H3K27ac correlates with regions of active transcription genome-wide (Tie 84 
et al., 2009; Wang et al., 2008b), and CBP-mediated acetylation can directly stimulate transcription 85 
by improving TF recruitment efficiency and promoter escape of PolII (Stasevich et al., 2014). 86 
Targeting the p300-HAT domain alone to enhancers using de-activated Cas9 nuclease (dCas9) 87 
and enhancer-specific guide RNAs (gRNAs) increases expression of enhancer-associated genes 88 
(Hilton et al., 2015). Thus, p300-mediated acetylation is sufficient for gene activation at 89 
endogenous enhancers and loci. 90 
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 91 
The localization of CBP activity at inappropriate enhancers is a critical factor in a subset of T-cell 92 
acute lymphoblastic leukemia (ALL). Somatic mutations create a new binding site for the 93 
transcription factor MYB upstream of the Tal1 oncogene resulting in recruitment of CBP. This leads 94 
to increased H3K27ac and formation of a new enhancer element driving oncogenic Tal1 95 
expression (Mansour et al., 2014).   96 
 97 
RNA could potentially impact the function of CBP and p300. Transcription of the antisense ncRNA 98 
khps1 from the promoter of the proto-oncogene SPHK1 helps to recruit p300 to the SPHK1 99 
promoter (Postepska-Igielska et al., 2015). Moreover, stable depletion of eRNA transcribed from 100 
an enhancer for chorionic gonadotropin alpha (Cga) decreased H3K27ac (Pnueli et al., 2015). A 101 
key open question is whether there is a direct mechanistic connection between eRNA and CBP 102 
function at regulatory elements.  103 
 104 
Here we demonstrate a direct interaction between CBP and RNA, including a large population of 105 
eRNAs. In vivo crosslinking and sequencing identified a subset of CBP-bound eRNAs associated 106 
with genes requiring CBP for their transcription. eRNA binding directly stimulates acetyltransferase 107 
activity of CBP in vitro, modulating H3K27ac levels. In cells, eRNA transcripts modulate their local 108 
chromatin environment, regulating H3K27ac to promote gene expression.  109 
 110 
Results 111 
 112 
CBP interacts with RNA in vivo 113 
The ability of CBP to interact directly with RNA in cells is untested, although some evidence 114 
suggests interactions. First, in a high throughput survey in HeLa cells, p300 emerged as a 115 
candidate RNA binding protein (Castello et al., 2012). Second, p300 is associated with the 116 
antisense ncRNA Khps1 in native RIP-qPCR experiments (Postepska-Igielska et al., 2015). Third, 117 
CBP co-purifies with RNA after formaldehyde cross-linking of nuclei (G Hendrickson et al., 2016). 118 
Moreover, CBP contains a number of Zn2+ finger motifs and regions of predicted intrinsic disorder, 119 
both of which have been proposed to have RNA binding properties (Castello et al., 2012; Wang et 120 
al., 2013).  121 
 122 
To validate the association of CBP with RNA without crosslinking, we carried out an RNA 123 
immunoprecipitation (RIP) experiment under native conditions from mouse embryonic fibroblasts 124 
(MEFs), and found that CBP IP co-purifies a population of bound RNA (Figure 1A, Figure S1A). To 125 
determine whether immunoprecipitated RNAs were interacting directly with CBP rather than 126 
indirectly through another CBP-bound protein, we used Photoactivatable ribonucleoside-enhanced 127 
crosslinking and immunoprecipitation (PAR-CLIP) (Figure 1B) (Hafner et al., 2010; Huppertz et al., 128 
2014). We observed PAR-CLIP signal corresponding to CBP that was dependent on labeling of the 129 
bound RNA with 4-thiouridine (4-SU) (Figure 1C, Figure S1B-E). We note that, similar to other 130 
PAR-CLIP results (Hafner et al., 2010; Kaneko et al., 2013; 2014a), cross-linked CBP-RNA 131 
complexes migrated in a less defined band due to crosslinking with heterogeneous RNAs. Labeling 132 
was sensitive to RNase treatment, confirming that the material crosslinked to CBP was RNA 133 
(Figure 1E-F; S1F-H).  134 
 135 
CBP-bound RNAs arise from sites of CBP binding 136 
To investigate how CBP interacts with RNA across the genome, we sequenced CBP PAR-CLIP 137 
libraries from two biological replicates. To control for background RNA binding events (Friedersdorf 138 
and Keene, 2014), we also prepared libraries for nuclear-localized and Flag epitope-tagged GFP 139 
(nGFP) and for the DNA binding domain of the yeast TF Gal4p (Gal4-DBD) (two replicates each) 140 
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(Figure 2A, Figure S2A). Statistically enriched RNA regions were identified on individual and 141 
pooled replicate datasets using PARalyzer v1.1, which takes advantage of the T-to-C transitions 142 
caused by photo-crosslinking to identify interaction sites (Corcoran et al., 2011). CBP PAR-CLIP 143 
read densities from each replicate were well correlated in the RNA regions called by PARalyzer on 144 
the separate replicates (Pearson's coefficient = 0.93; Pearson's coefficient = 0.95 for common 145 
regions between replicates) (Figure S2B). Having confirmed the reproducibility of our CBP PAR-146 
CLIP sequencing experiments, we pooled the replicates to identify a consensus set of CBP-bound 147 
RNA regions for downstream analyses. This resulted in 11,041 CBP-bound RNAs (CBP-RNAs) 148 
with a median size of 19bp (Figure S2C). There were 2367 bound RNAs in common between 149 
Gal4-DBD and nGFP controls, 2922 between CBP and Gal4-DBD, and 2020 between CBP and 150 
nGFP (Figure S2D±F); in total, ~71% (7,835) of CBP-RNAs did not appear in the background 151 
controls, suggesting that these represent specific signal from CBP-associated RNAs (Figure S2G, 152 
Table S1). We did not detect RNA-dependent interactions between CBP and other eRNA 153 
interacting proteins, such as Mediator (Lai et al., 2013) or NELF (Schaukowitch et al., 2014) under 154 
native (Figure S2H) or PAR-CLIP (Figure S2I) conditions. Using published ChIPseq data (Kagey et 155 
al., 2010; Sun et al., 2011), we found no difference in Med-1 signal at CBP-RNAs compared to 156 
background RNAs (Figure S2J), although NELF signal was enriched at CBP-RNAs, suggesting 157 
active transcription at these regions (Figure S2J). Thus, we were unable to detect co-binding of 158 
CBP and other eRNA interacting proteins to the same RNAs. 159 
We compared the distribution of CBP PAR-CLIP signal with published CBP ChIPseq (Kasper et 160 
al., 2014) and GROseq (Meng et al., 2014) datasets in MEFs. Genome browser views of bound 161 
RNA regions and corresponding reads, such as at a target enhancer upstream of Tet2 (Figure 2B-162 
C), revealed increased PAR-CLIP read density. In many locations such as the Tet2 enhancer, CBP 163 
PAR-CLIP reads mapped to regions of chromatin showing nascent transcription (by GROseq) and 164 
CBP occupancy (by ChIPseq; Figure 2B-C). The majority of CBP-RNAs (73%) were found in 165 
intergenic (47%) or intronic regions (26%) of the genome similar to CBP itself (72%; 43% 166 
intergenic, 29% intronic) (Figure 2D). The remaining CBP-RNAs arise from exons (23%) and very 167 
few (4%) from promoters (Figure 2D). As only 4% of CBP chromatin binding sites are at exons, we 168 
examined the distribution at exons and promoters in greater detail. The high level of exonic CBP-169 
RNAs relative to CBP binding appears to result from increased false-positives due to the high 170 
transcription and stability of exons. First, actual PAR-CLIP reads are enriched at promoters and 171 
distal sites, compared to exons (Figure S2K). Second, the enrichment for CBP-RNAs at exons was 172 
relatively low, especially when compared to high transcription at exons (Figure S2K-L). Third, the 173 
TSS-1kb window used to define promoters limited the number of CBP-RNAs assigned to 174 
promoters. Therefore, the distribution of CBP-RNAs reflects patterns of CBP chromatin binding 175 
genome-wide.  176 
 177 
Compared to RNAs bound in the negative control libraries, CBP-RNAs were enriched for CBP 178 
ChIPseq signal (Figure 2E) and were slightly more likely to comprise accessible chromatin (Figure 179 
2F). CBP-RNAs had more nascent transcription by GROseq (Figure 2G), and were enriched for 180 
more stable RNA transcripts in total RNAseq data (Figure S2M). We then compared levels of 181 
nascent transcription (GROseq) to stable RNA transcripts (total RNAseq) at CBP-RNAs. The CBP-182 
RNAs most enriched for GROseq reads also displayed high-read density in total RNAseq data 183 
(Figure S2N) and vice versa (Figure S2O). Nevertheless, CBP-RNAs with low enrichment in total 184 
RNAseq still demonstrated transcription by GROseq (Figure S2O, bottom deciles). Consistent with 185 
this, CBP-RNAs arising from stable transcripts at exons were strongly enriched for total RNAseq 186 
reads, but GROseq reads were strongly enriched at promoters and distal regions (Figure S2P). 187 
This reflects the ability of GROseq to detect the often-unstable, nascent RNA transcripts at these 188 
locations, where most CBP-RNAs arise (Figure 2D), and suggests that CBP-RNAs contain an 189 
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abundant population of nascent RNAs. There was an inverse correlation between peak-to-peak 190 
distance of CBP ChIPseq and PAR-CLIP signal when considering intersecting CBP and CBP-191 
RNAs (Figure S2Q), with a higher Spearman co-efficient at short distances. Importantly, there was 192 
a consistent and more robust correlation with CBP ChIP signal for CBP-RNAs than for Gal4-DBD 193 
or nGFP control RNAs (Figure S2Q). Taken together these data demonstrate that CBP-RNAs 194 
localize at sites with nascent RNA transcription and within regions of chromatin bound by CBP. 195 
 196 
CBP binds to eRNAs 197 
As CBP-RNAs originated from transcribed chromatin regions occupied by CBP, two hallmarks of 198 
enhancers, we sought to determine whether CBP-RNAs corresponded to eRNAs. To account for 199 
the typical length of eRNAs, we focused on 1,138 locations where the center of the CBP-RNAs 200 
was less than 3.5kb from the nearest CBP peak and where CBP-ChIPseq and PAR-CLIP signal 201 
were strongly correlated (Figure S2Q) (De Santa et al., 2010; Kim et al., 2010). These CBP-RNAs 202 
close to CBP-ChIPseq peaks showed strong enrichment for PAR-CLIP reads (Figure S3A) 203 
compared to CBP-RNAs arising further from a CBP peak. They were also enriched for CBP 204 
ChIPseq and GROseq reads (Figure S3B-C), suggesting a positive relationship between PAR-205 
CLIP signal and levels of CBP recruitment and transcription. To account for differences in CBP 206 
chromatin binding genome-wide (Figure 2D), we divided CBP peaks proximal to CBP-RNAs into 207 
promoter (TSS-1kb, 133 peaks, 13.5%), exonic (256 peaks, 26.2%) and distal (intergenic/intronic, 208 
587 peaks 60.1%) sub groups (Figure 3A, Figure S3D). Sites with the highest enrichment for PAR-209 
CLIP reads corresponded to regions most enriched for CBP in all three groups; the highest levels 210 
of CBP are found at the most enriched PAR-CLIP sites in promoter and distal regions - classical 211 
regions of CBP binding (Figure S3E). Locations with highest CBP binding (Figure S2F) and 212 
GROseq signal (Figure S3G) displayed the greatest enrichment for PAR-CLIP reads across all 213 
three groups. The distribution of reads across all three groups demonstrated slight enrichment for 214 
CBP binding at promoters and distal locations (Figure S3H-I), lower levels of transcription at distal 215 
sites (Figure S3J-K) but enrichment for PAR-CLIP reads at promoters and distal sites compared to 216 
exons (Figure S3L-M). The abundance of CBP-RNAs corresponded to the level of CBP chromatin 217 
binding at actively transcribed regions. Therefore, RNA binding to CBP appears to be locus-218 
specific: CBP-RNAs arise from transcribed regions at locations where CBP binds to chromatin.  219 
 220 
The large number of distal CBP-RNAs (Figure 2D) reflects the prevalence of CBP binding to 221 
enhancers in distal regions of the genome (Kasper et al., 2014). Active enhancers have high CBP 222 
occupancy and nascent transcription of eRNAs (Creyghton et al., 2010; Kim et al., 2010); our data 223 
suggests that these are also common features of CBP-RNA sites. Distal CBP-RNA sites display bi-224 
directional RNA transcription, enriched CBP occupancy, more accessible chromatin (increased 225 
DNAse I hypersensitivity) and elevated levels of H3K27ac (Figure 3B). Furthermore, distal sites 226 
have higher H3K27ac (Figure S3N) and nascent transcription by GROseq (Figure S3O) compared 227 
to non-RNA interacting control CBP binding sites. Moreover, distal CBP-RNAs are enriched for 228 
H3K4me1 and depleted for H3K4me3, a characteristic profile of lysine methylation found at 229 
enhancers (Figure 3C-D) (Creyghton et al., 2010; Heintzman et al., 2007). CBP therefore appears 230 
to interact with eRNAs at distal enhancers (referred to hereafter as CBP-eRNA). We note that 231 
within CBP-eRNA loci, distal regions of strong GROseq signal are associated with elevated 232 
H3K4me3 (Figure 3A) reflecting more active transcription at these sites. We asked whether CBP-233 
eRNAs had a chromatin signature of active enhancers, characterized by elevated H3K27ac. Of 234 
766 CBP-RNAs intersecting H3K4me1, 532 (69.5%) also overlapped H3K27ac peaks (Figure 3E, 235 
Figure S3Q-S). However, of 533 distal CBP-eRNAs that intersect H3K4me1, 459 (86.1%) 236 
overlapped H3K27ac (Figure 3F, Figure S3P-R) and thus displayed an active enhancer signature. 237 
 238 
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Enhancers often regulate expression of adjacent genes (Kim et al., 2010; Lai et al., 2013; Li et al., 239 
2013; Melo et al., 2013; Mousavi et al., 2013). Gene ontology (GO) analysis revealed that the 240 
genes nearest to CBP-eRNAs are significantly enriched for transcription regulators, including TFs, 241 
mediator subunits and epigenetic regulators (Figure S3S and Table S2). Furthermore, motif 242 
analysis identified binding sites for known CBP-interacting TFs (Table S3) (Bedford et al., 2010). 243 
The amount of CBP and p300 bound at promoters and enhancers is a poor predictor of the 244 
CBP/p300 requirement for expression of proximal genes (Kasper et al. 2014). Genes associated 245 
with CBP-eRNA (Table S4) tend to be downregulated upon CBP knockdown relative to genes not 246 
associated with CBP-eRNA (Figure S3T) (data from published microarray (Kasper et al., 2014)). 247 
We used RT-qPCR to examine the effect of CBP knockdown (control in Figure S3U) on newly 248 
identified eRNA transcripts and associated mRNA expression at a subset of genes (Figure 3G-H). 249 
The majority of tested mRNAs (8/9; 89%) were downregulated upon CBP knockdown (Figure 3H), 250 
and 4/8 (50%) of the corresponding eRNAs were also decreased (Figure 3G), indicating that these 251 
selected genes are direct targets of CBP. Overall, our data support the conclusion that distal CBP-252 
eRNA regions represent a subset of active enhancers where eRNAs bind to CBP, and whose 253 
associated genes require CBP activity for expression. 254 
 255 
In vitro reconstitution of CBP RNA binding 256 
To investigate RNA binding to predicted RNA binding regions (RBRs) within CBP (BindN (Wang 257 
and Brown, 2006), Figure 4A, Figure S4A), we purified full length CBP (CBP-FL) from Sf9 cells 258 
(Figure S4B, left panel). Using an RNA pull-down (Bonasio et al., 2014) with in vitro transcribed 259 
RNA probes corresponding to eRNA-Klf6 (Figure 4B) and eRNA-Med13l (Figure 4C), we observed 260 
RNA interactions with CBP-FL (but not in control experiments), suggesting that CBP directly binds 261 
to RNA (Figure 4C-D, S4C-D). 262 
 263 
RNA binding predictions for CBP (Figure 4A) suggested a highly basic region (residues 1561-264 
1620) within the core HAT domain might contain the observed RNA binding activity. This region 265 
shares >90% identity with p300 and comprises 49 basic residues that are evolutionarily conserved 266 
and disordered (Delvecchio et al., 2013; Liu et al., 2008; Wang et al., 2008a; Yuan and Giordano, 267 
2002). As highly basic and disordered regions are implicated in RNA binding (Castello et al., 2012; 268 
2016; He et al., 2016), including RNA binding to epigenetic factors such as SCML2 and JARID2 269 
(Bonasio et al., 2014; Kaneko et al., 2014a), we investigated the predicted RBR in the HAT 270 
domain. CBP1196-1718 (CBP-HATwt), which contains all functional domains necessary for HAT 271 
activity (Delvecchio et al., 2013), was purified from bacteria (Figure S4B, right panel). RNA pull-272 
down using sequences from nascent eRNAs (e-Klf6, e-Tet2, e-Klf4), processed lncRNAs 273 
(HOTAIR1-300, Gas5, Meg3) and exonic RNAs (Id-1 (exon-1), Bbs2 (exon-1), Klf2 (exon-3)) (Figure 274 
4E-F, Figure S4E-G), demonstrated that CBP-HATwt in isolation could bind to multiple different 275 
RNA sequences. However, we noted that binding to eRNA sequences was more consistent than 276 
binding to RNAs lncRNAs and exons (Figure S4G). Thus, CBP-HATwt recapitulated the interaction 277 
of CBP-FL with RNA (Figure 4B-D, Figure S4C-D), and displayed a general rather than sequence-278 
specific RNA binding activity in vitro. As CBP-RNAs were enriched at sites of CBP chromatin 279 
binding (Figure 2), this supports a genomic locus-specific binding model, where RNAs transcribed 280 
proximal to CBP can bind to the RBR independent of RNA sequence. 281 
 282 
Next, we used RNA electrophoretic mobility shift assays (EMSA) to evaluate RNA binding of CBP-283 
HATwt to radiolabeled eRNA target sequences (Table S5). All sequences displayed a robust 284 
mobility shift when titrated with CBP-HATwt (Figure 4G-H, S4H, S4M, S4N). Moreover, binding to 285 
labeled eRNA-Mdm2 (Figure 4I) or eRNA-YY1 (Figure S4M: (iv)) was outcompeted by identical 286 
unlabeled eRNA probes. Importantly, single strand (ss) and double strand (ds) DNA with the same 287 
sequence could not compete with the CBP-eRNA interactions (Figure 4J), demonstrating that 288 
CBP-HATwt binds specifically to RNA in vitro. 289 
 290 
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The predicted RBR in the HAT domain (Q1559-K1608) (Figure S4A) forms a highly basic 291 
disordered loop which was proteolytically cleaved in available x-ray crystallographic structures of 292 
the p300 HAT domain (Delvecchio et al., 2013; Liu et al., 2008). Binding of eRNA-Klf6 to CBP in 293 
pull-downs (Figure 4E-F, Figure S4E) and eRNA-Mdm2 in EMSA (Figure 4K) was severely 294 
decreased when Q1559-K1608 was deleted (CBP-HATdelta-loop) (Figure S4I). To test whether the 295 
charge of the loop was important for RNA binding, we mutated basic residues within the loop to 296 
acidic residues not predicted to interact with RNA (CBP-HATmutant-loop) (Figure S4I). We maintained 297 
lysine residues that are known targets for CBP mediated auto-acetylation regulating CBP-HAT 298 
activity and positively-charged residues important for lysine targeting by CBP (Liu et al., 2008; 299 
Thompson et al., 2001; 2004). Notably, the acetylation state of the RBR loop was important for 300 
RNA binding, as CBP-HATwt only exhibited detectable RNA binding when co-expressed with lysine 301 
deacetylase ySir2 (Figure S4J), suggesting interplay between auto-acetylation of the RBR loop 302 
and RNA binding. In contrast, CBP-HATmutant-loop displayed severe defects in RNA binding when co-303 
expressed with ySir2, both in RNA pull-downs with eRNA-Klf6 (Figure 4E-F, Figure S4E) and in 304 
RNA EMSAs using radiolabelled eRNA probes (Figure 4L, Figure S4K), confirming the importance 305 
of basic residues within the RBR for RNA binding to the CBP-HAT domain. 306 
 307 
We next asked whether CBP-eRNAs could interact with the identified RBR in CBP using PAR-308 
CLIP in cells. We quantified binding of CBP-eRNA to full-length CBPwt, CBPdelta-loop or CBPmutant-loop 309 
in cells by PAR-CLIP followed by RT-qPCR (Figure 4M, control in Figure S4L). CBPdelta-loop and 310 
CBPmutant-loop showed drastically reduced binding to CBP-eRNAs compared to CBPwt (Figure 4M), 311 
suggesting that the identified RBR within the regulatory loop is the predominant but not the only 312 
site of interaction for CBP with eRNAs. Overall, the in vitro RNA binding experiments demonstrate 313 
that CBP can directly associate with RNA. Moreover, a specific RNA-binding sequence located 314 
within a basic loop that is part of the HAT domain, constitutes a previously unrecognized RBR 315 
within CBP. The binding data suggest that CBP can bind to RNA in a locus-specific manner, 316 
independent of RNA sequence; thus a bias towards eRNAs is observed due to the high 317 
recruitment of CBP to enhancer regions where it interacts with nascent eRNA transcripts. 318 
 319 
CBP acetyltransferase activity is stimulated by RNA binding 320 
Having defined an RBR within the HAT domain of CBP, we next investigated whether RNA binding 321 
affects the HAT activity of CBP, using a radioactive filter-binding assay (Figure S5A). Increasing 322 
concentrations of two different eRNAs, eRNA-Ccnd1 and eRNA-Klf6, stimulated CBP HAT activity 323 
(Figure 5A). Both eRNAs stimulated activity in a dose dependent manner, but the magnitude and 324 
pattern of activity differed slightly between eRNA species. There was no equivalent stimulation 325 
when titrating control Ccnd1 ssDNA or dsDNA (Figure 5A). Stimulation was independent of RNA 326 
sequence, but required RNA binding to the RBR: HOTAIR1-300 and Id-1 (exon-1), which bound 327 
robustly to CBP-HATwt (Figure S5B) stimulated activity, but Meg3, which bound poorly, did not 328 
(Figure S5B-C). Importantly, HAT activity did not increase in CBP deleted for the RBR (CBP-329 
HATdelta-loop, Figure 5B). Thus, RNA binding to the RBR within the HAT domain of CBP stimulates 330 
HAT activity.  331 
 332 
Next, we determined whether RNA binding increases CBP-dependent histone modifications. CBP 333 
acetylates distinct lysine residues, including H3K27ac and H3K18ac on histone H3 and H4K5ac on 334 
histone H4 in vitro (Henry et al., 2013). We repeated the HAT assay using reconstituted 335 
recombinant nucleosomes (Figure S5D) and assayed by western blot. The level of both H3K27ac 336 
and H4K5ac increased as eRNA concentration was titrated (Figure 5C-E, Figure S5E-G), 337 
confirming that increased activity with RNA translates to higher H3K27ac (Figure 5C) and H4K5ac 338 
(Figure 5D) in vitro. Stimulation was independent of RNA sequence; eRNA-YY1 (Figure 5E), 339 
eRNA-Mdm2, eRNA-Ccnd1 and lncRNA-HOTAIR1-300 all stimulated both H3K27ac and H4K5ac 340 
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(Figure S5E-G), although the different sequences generated different profiles of acetylation. The 341 
effect was also observed for recombinant H3 in isolation (Figure S5H, quantified in Figure S5I). 342 
The dose response is U-shaped; at high molar ratios of RNA to CBP-HAT there was a drop in 343 
H3K27ac (Figure 5C, Figure S5I) and H4K5ac (Figure 5D), which could result from CBP 344 
interactions with RNA outside of the primary CBP-RBR at high RNA concentrations. Consistent 345 
with this hypothesis, the activity of CBP-HATdelta-loop also decreased at high RNA concentrations 346 
(Figure 5B); we note that most eRNAs have low abundance in different systems (Kim et al., 2010; 347 
Lam et al., 2013; Li et al., 2013). When the experiment was repeated with recombinant human 348 
MOF (hMOF) there was no stimulation of H4K16ac, the major acetylation site of hMOF (Figure 349 
S5J). MYST-type acetyltransferases such as hMOF, although also regulated by acetylation, do not 350 
contain a CBP/p300-like RBR (Wang et al., 2008a; Yuan et al., 2012). 351 
 352 
Our data demonstrate that RNA binding to the HAT domain of CBP, through the identified RBR, 353 
stimulates the acetyltransferase activity of CBP in an RNA concentration-dependent manner, 354 
generating increased levels of H3K27ac and H4K5ac in vitro. 355 
 356 
Mechanism of RNA stimulation of acetyltransferase activity 357 
CBP/p300 display a unique mechanism of regulation among acetyltransferase families whereby a 358 
basic activation loop within the HAT domain acts as a pseudo-substrate, binding to the active site 359 
and auto-inhibiting HAT activity by preventing substrate binding (Liu et al., 2008; Thompson et al., 360 
2004; Wang et al., 2008a). Acetylation of the activation loop results in its displacement, thus 361 
allowing substrate binding to the active site. In steady-state HAT assays, a loss of auto-inhibition is 362 
observed as a decrease in the concentration of substrate needed to reach half maximum 363 
acetylation rate (Km) (Thompson et al., 2004). Remarkably, the location of the CBP/p300 activation 364 
loop largely overlaps the position of the RBR within the HAT domain (Figure 4A, Figure S4A). We 365 
therefore tested whether eRNA binding to the RBR could stimulate the HAT activity of CBP 366 
through a similar reduction of auto-inhibition.  367 
 368 
We adapted our radioactive filter binding assay to evaluate the steady-state kinetic mechanism of 369 
stimulation of CBP activity by eRNA (Bowers et al., 2010) (Figure 5F-G; kinetic parameters are 370 
summarized in Figure S5K and a model for activation in Figure 5J). Our calculated value of Km(H3-1-371 
21) for CBP-HATwt (Km(H3-1-21)= 44.55 +/- 3.99 uM) (Figure 5F) closely matches previous values for 372 
recombinant p300 HAT domain (Km(H4-15) = 40 +/- 8 uM) (Thompson et al., 2004). Consistent with 373 
our model, addition of 10nM eRNA-Mdm2 decreased the Km(H3-1-21) of CBP-HATwt from 44.55 +/- 374 
3.99 to 26.42 +/- 3.55uM (Figure 5F). We note that while 10nM eRNA also slightly decreased the 375 
Kcat (Figure 5F), the specificity constant Kcat/Km was increased, reflecting an increase in catalysis 376 
(Figure 5H). Hence, in common with acetylation of the activation loop, the stimulation of CBP HAT 377 
activity by eRNA binding is due to its increased affinity for histone substrate rather than to an 378 
alteration of the catalytic mechanism. 379 
 380 
To confirm this mechanism, CBP-HATmutant-loop, which does not bind to eRNA (Figure 4N), 381 
displayed no change in the Km with 10nM eRNA (Figure 5G). Indeed, the Km of CBP-HATmutant-loop in 382 
the absence of eRNA was already decreased (Km(H3-1-21)= 27.30 +/-5.65 uM) compared to CBP-383 
HATwt (Km(H3-1-21)= 44.55 +/- 3.99 uM) (Figure S5K).  This indicates that mutation of basic residues 384 
to acidic residues within the loop is sufficient to displace the loop from the active site and thus 385 
mimic the effect of eRNA binding. Inclusion of eRNA, which does not interact with the mutant loop, 386 
has no further effect on the Km and consequently there is no increase in Kcat/Km(H3-1-21) (Figure 5I, 387 
Figure S5K). Importantly, Kcat with 10nM RNA was similar for both CBP-HATmutant-loop and CBP-388 
HATwt, which suggested that the decrease in Kcat observed in both cases was independent of 389 
eRNA binding to the RBR (compare Figures 5F and 5G, values in Figure S5K). However, as 10nM 390 
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RNA did not change the Km of CBP-HATmutant-loop, the specificity constant Kcat/Km was slightly 391 
decreased (Figure 5I, Figure S5K). These data indicate that eRNA binding to the RBR within the 392 
activation-loop results in its displacement from the active site of CBP. This allows improved 393 
substrate binding, decreases the Km in the presence of eRNA, and thus enhances the HAT activity 394 
of CBP (see model in Figure 5J). 395 
 396 
eRNAs modulate the acetyltransferase activity of CBP in vivo 397 
Our data demonstrate that CBP binds to RNAs transcribed close to CBP binding sites such as at 398 
the YY1 enhancer (Figure 6A); recruitment of CBP to active enhancers results in binding to 399 
eRNAs, and that eRNA binding to the HAT domain of CBP stimulates its acetyltransferase activity.  400 
 401 
We next asked whether depletion of CBP-eRNAs in cells reduces histone acetylation in a locus-402 
specific manner. Depletion of eRNA transcripts can specifically reduce expression of mRNA 403 
regulated by the target enhancer (Kim et al., 2010; Lai et al., 2013; Li et al., 2013). RT-qPCR 404 
following transfection of antisense-oligonucleotides (ASO) targeting eRNA-YY1 (Figure 6A, Figure 405 
S6A), compared to GFP ASO control, revealed specific depletion of the targeted eRNA-YY1 and 406 
reduction of the adjacent coding mRNA (Figure 6B, Figure S6E). Importantly, eRNA and mRNA at 407 
non-targeted Ccnd1 loci (Figure 6B, bottom panel; Figure S6E) was not significantly reduced upon 408 
depletion of eRNA-YY1. We note that eRNA-YY1 depletion also slightly affects expression of Tet2 409 
mRNA, likely indirectly through depletion of YY1 protein, as the Tet2 promoter contains a YY1 410 
motif (TRANSFAC, (Matys et al., 2006)). Similarly, ASO that depleted eRNA-Ccnd1 (Figure S6B) 411 
reduced levels of eRNA and adjacent coding mRNA at Ccnd1, but not at non-targeted YY1 and 412 
Tet2 loci (Figure 6C, Figure S6E). 413 
 414 
We depleted eRNA-YY1 and found a similar reduction of H3K27ac (Figure 6D) and H3K18ac 415 
(Figure 6E), whereas there was no significant change in acetylation at the Ccnd1 control enhancer 416 
and promoter loci (Figure 6D-E, bottom panel) or at Tet2 control loci (Figure S6F-G, bottom panel). 417 
There was also no change in CBP occupancy at enhancer or promoter regions (Figure 6F). 418 
Similarly, depletion of eRNA-Ccnd1 decreased H3K27ac (Figure 6G) and H3K18ac (Figure 6H) at 419 
the Ccnd1 enhancer and promoter, but produced no change in acetylation at the YY1 enhancer 420 
and promoter (Figure 6G-H, bottom panels) and no change in CBP occupancy (Figure 6I). 421 
Acetylation was also reduced at the Tet2 enhancer and promoter upon depletion of eRNA-Tet2 422 
(Figure S6H-I), with no alteration in CBP binding (Figure S6J) or acetylation at YY1 control loci. 423 
(we note that this did not lead to decreased Tet2 mRNA, consistent with our previous observation 424 
that loss of CBP did not reduce Tet2 mRNA levels in Figure 3H). Importantly, for all three 425 
examples, eRNA depletion caused decreased acetylation specifically at the target enhancer and 426 
promoter, but not at control enhancer and promoter loci.  427 
 428 
Our findings lead to a model (Figure 7) where CBP binding to specific eRNA transcripts regulates 429 
CBP acetyltransferase activity in cis. This results in a local increase in CBP-dependent histone 430 
acetylation at the same enhancer and target promoter regions. eRNA binding therefore contributes 431 
to enhancer-specific patterns of histone acetylation at regulatory regions. 432 
 433 
Discussion 434 
Our results provide direct evidence of RNA binding to CBP in cells. We show that CBP interacts in 435 
a locus-specific manner with RNAs transcribed proximal to sites of CBP chromatin binding. By 436 
interacting with a CBP/p300-specific RBR located within its catalytic HAT domain, RNA stimulates 437 
the HAT activity of CBP. This observation has particular importance at enhancers, where CBP 438 
binding, histone acetylation, and eRNA production are interconnected. Localizing acetyltransferase 439 
activity to enhancers is sufficient to promote transcription of associated genes (Hilton et al., 2015). 440 
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Our findings link these events in a mechanistic manner: eRNA binding to CBP in cis stimulates the 441 
localized acetyltransferase activity at enhancers, increasing H3K27ac and H3K18ac at the 442 
enhancer and, importantly, at the target promoter, thereby promoting gene expression. 443 
Nevertheless, further work is needed to fully elucidate the role of CBP dependent acetylation at 444 
enhancers in regulating gene expression.  445 
 446 
The mechanism of regulation by activation loop is unique to CBP/p300 among acetyltransferases 447 
(Wang et al., 2008a). Remarkably, we show that this same motif renders the HAT activity of CBP 448 
sensitive to RNA (Figure 5F-G). This feature may be unique to CBP/p300, as the activity of the 449 
acetyltransferase hMOF was not affected by RNA (Figure S5J). Our observation that acetylation 450 
was important for RNA binding (Figure S4K) suggests a possible interplay between RNA binding 451 
and auto-acetylation of the loop region. Moreover, CBP activity is also sensitive to interactions with 452 
transcription factor binding partners (Chen et al., 2001; Perissi et al., 1999). Direct binding of 453 
ncRNAs to the chromatin modifying enzymes PRC2 (Cifuentes-Rojas et al., 2014; Kaneko et al., 454 
2014b), and DNMT1 (Di Ruscio et al., 2013) modulate their function. Our data adds CBP to the list 455 
of enzymes whose function is modified by RNA binding, and we demonstrate that eRNA in 456 
particular contributes to an active chromatin profile through stimulation of CBP HAT activity in cis.  457 
 458 
Our data suggests that RNA binding to CBP could be similar to PRC2 in using a promiscuous 459 
binding model, defined as the ability to bind to many RNA sequences with broadly similar affinities 460 
(Cifuentes-Rojas et al., 2014; Davidovich et al., 2015; Kaneko et al., 2013; 2014a). RNA binding to 461 
CBP also appears to be locus-specific: CBP binds to RNAs where it is recruited to chromatin. CBP 462 
bound at promoters may therefore also be regulated by interactions with RNA, although the 463 
prevalence of enhancer bound CBP (Kasper et al., 2014) results in a strong bias towards eRNA 464 
binding. Promiscuous, locus-specific RNA binding has obvious benefits for a transcriptional co-465 
activator such as CBP with a broad genome-wide binding profile, allowing RNAs to stimulate local 466 
CBP activity regardless of their sequence. Moreover, variations in binding between RNAs could 467 
generate locus-specific activity and acetylation profiles, thus enabling fine-tuning of target gene 468 
expression. This model enables a de-coupling of CBP/p300 recruitment from histone acetylation 469 
and transcriptional output, helping to explain why CBP/p300 recruitment is a poor predictor of gene 470 
activation (Bedford et al., 2010; Kasper et al., 2014). Consistently, depletion of CBP-eRNAs 471 
decreased H3K27ac and H3K18ac specifically at associated promoters and modulated gene 472 
expression (Figure 6F-G, I-J).  473 
 474 
In conclusion, we show that RNAs transcribed proximal to CBP binding sites directly interact with 475 
CBP in cis. Binding to the RBR within the catalytic HAT domain of CBP ± a region critical for 476 
regulating HAT activity - allows substrate to bind more easily and thereby stimulates the HAT 477 
activity of CBP. At active enhancers, CBP binds to eRNAs leading to elevated histone acetylation 478 
and increased transcription of target genes (Figure 7). In this model, CBP-mediated histone 479 
acetylation can be regulated independently from CBP recruitment, and allows enhancer- and gene-480 
specific tuning of acetylation. By stimulating CBP activity, RNA binding can generate a tailored 481 
chromatin environment at target genes to fine-tune transcriptional output.  482 
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Figure legends 504 
 505 
Figure 1: CBP interacts with RNA in vivo  506 
A) Native RNA-IP of CBP. Top, RNA immunprecipitated with CBP was purified and imaged with 507 
SYBR gold. Bottom, western blot for CBP.  508 
B) Schematic of PAR-CLIP protocol. 4-Thiouridine (4-SU).  509 
C) CBP PAR-CLIP required 4-SU: top, autoradiography; bottom, western blot for CBP on PAR-510 
CLIP membrane.  511 
D) Quantification of CBP PAR-CLIP. Error bars represent mean +/- s.e.m; n=4. 512 
E) CBP PAR-CLIP signal was sensitive to RNAse. 1x RNAse cocktail contained: RNAse A 513 
(0.01mU/ul) + RNase T1 (0.4mU/ul).  514 
F) Quantification of RNase titration. Error bars represent mean +/- s.e.m; n=4; P-values from two-515 
tailed 6WXGHQW¶V t-test: *P< 0.05; **P< 0.01; ***P< 0.001. 516 
 517 
Figure 2: CBP-RNAs arise at regions of CBP enrichment. 518 
A) Autoradiography of CBP PAR-CLIP and nls-GFP (nGFP) and yeast Gal4 DNA binding domain 519 
(Gal4-DBD) background control. Membrane excised for library preparation (Dashed box). 520 
B) UCSC genome browser view of CBP-RNA upstream of the Tet2 promoter. Top; GROseq signal 521 
(+ strand purple, - strand grey); CBP-RNA (PARalyzer) orange bars; 2 replicates PAR-CLIP reads 522 
(orange/purple); CBP peaks (blue bars); 2 replicates CBP reads (light blue/dark blue). 523 
C) Close-up of box from G). Sense strand (s) and antisense strand (as) 524 
D) Distribution of CBP and CBP-RNA by genome region (Promoter = 1kb upstream of TSS). 525 
E-G) Read density over CBP-RNAs and enriched control RNAs. CBP peaks were randomly 526 
downsampled to match the size of the background dataset (5581); F) CBP ChIPseq signal 527 
(GSE54453, (Kasper et al., 2014)); G) DNaseI hypersensitivity (ENCODE, GSE37074); H) 528 
GROseq (GSM1524922, (Meng et al., 2014)). P-values from Mann-Whitney U-test. 529 
 530 
Figure 3: CBP binds to eRNAs and directs gene expression from CBP-eRNA enhancers  531 
A) Heatmaps of RNA bound CBP peaks (<3.5kb). CBP peaks were categorized into Promoter 532 
(TSS-1kb), Exon and Distal (Intronic/Intergenic). Heat maps show +/- 2.5kb window from centre of 533 
CBP peak, reads were binned over 50bp.   534 
B) UCSC genome browser views of CBP-eRNA regions proximal to Klf6, Sp3, Med13l, Yy1, Ccnd1 535 
and Tet2 genes. Top; GROseq signal (Sense, purple; antisense, grey); CBP-RNAs (PARalyzer) 536 
orange bars; 2 replicates PAR-CLIP reads (orange/purple); CBP peaks (blue bars); 2 replicates 537 
CBP reads (light blue/dark blue); H3K27ac reads (green). Sense strand (s) and antisense strand 538 
(as) directions are indicated. 539 
C-D) Reads at CBP-RNAs sorted by genome region: C) H3K4me3; D) H3K4me1. P-values from 540 
Mann-Whitney U-test. 541 
E-F) Venn diagrams show CBP ChIPseq peaks with H3K4me1 intersecting H3K27ac for: E) CBP-542 
RNAs; F) CBP-eRNAs. P-values from permutation test with random regions restricted to TSS-543 
40kb. 544 
G-H) RT-qPCR of G) CBP-eRNAs. Strand is indicated (s=sense, as=antisense); and H) Nearest 545 
gene. Data show log2 fold change between control adenoviral GFP (Adv-GFP, green) or 546 
knockdown with adenoviral Cre (Adv-Cre, purple); n=3.  547 
 548 
Figure 4: In vitro reconstitution of CBP RNA binding   549 
A) CBP domains and RNA binding prediction (BindN). Non-binding residues (green) and binding 550 
residues (red) are indicated. Magnified sequence shows strong predicted RNA binding region in 551 
the CBP-HATwt domain. 552 
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B-C) In vitro pull down of B) eRNA-Klf6s and C) eRNA-Med13ls. s=sense, as=antisense strand 553 
RNA. Replicate images in Figure S4C-D. 554 
D) Quantification of RNA-pulldown data in B-C. n=3. 555 
E) In vitro pull down of eRNA-Klf6s. RNA Input and protein fractions in Figure S4E). 556 
F) Quantification of RNA-pulldown data in B-C. n=3. 557 
G-H) RNA EMSA of eRNA probes using CBP-HATwt. G) eRNA-Mdm2s; H) eRNA-Med13ls. 558 
Replicate images in Figure S4M; whole gel images in Figure S4N. 559 
I-J) Competition binding RNA EMSAs. Binding of 2nM 32-P radiolabelled eRNA-Mdm2 to CBP-560 
HATwt (2000nM) was competed with: I) 0-20nM unlabelled eRNA-Mdm2; J) 1nM, 10nM and 20nM 561 
un-labeled eRNA-Mdm2 (RNA), dsDNA or ssDNA with the same sequence.  562 
K) RNA EMSA using CBP-HATdelta-loop. eRNA-Med13l was titrated with 0-8000nM CBP-HATdelta-loop. 563 
(*) CBP-HATwt (2000nM).  564 
L) RNA EMSA using CBP-HATmutant-loop. eRNA-Med13l was titrated with 0-8000nM CBP-HATmutant 565 
loop. (*) CBP-HATwt (2000nM).  566 
M) RBR mediates RNA binding to FL-CBP in vivo. PAR-CLIP for GFP-tagged CBPwt, CBPdelta-loop or 567 
CBPmutant-loop in MEFs was followed by RT-qPCR for eRNA-Ccnd1, eRNA-Tet2, eRNA-YY1, eRNA-568 
Klf6. Control lncRNA Malat-1 was not identified by PARalyzer v1.1. P-values from two-tailed 569 
6WXGHQW¶V t-test: *P< 0.05; **P< 0.01; ***P< 0.001. 570 
 571 
Figure 5: CBP acetyltransferase activity is stimulated by RNA binding  572 
A) RNA stimulated CBP HAT activity in filter binding assays. 5nM CBP-HATwt was titrated with 0-573 
40nM eRNA (eRNA-Ccnd1 and eRNA-Klf6) or control (dsDNA/ssDNA with same sequence). Data 574 
shows fold change in rate (Vmax/[E], (s-1)) from 0nM RNA. Shaded regions show mean +/- s.e.m 575 
(RNA n=3, control n=1). s=sense, as=antisense strand RNA.  576 
B) Stimulation of CBP HAT activity required the RBR. 1nM CBP-HATwt or CBP-HATdelta-loop was 577 
titrated with 0-40nM eRNA-Mdm2. Shaded regions show mean +/- s.e.m (n=4).   578 
C-E) Western blot HAT assay using recombinant nucleosome substrate. 1nM CBP-HATwt was 579 
titrated with 0-10nM eRNA-YY1as. RNA stimulated: C) H3K27ac (H3 normalized) and; D) H4K5ac 580 
(H4 normalized). E) Western blot for H3K27ac, H4K5ac and H3/H4. Coomassie (bottom panel) 581 
shows individual histones.  582 
F-G) Steady state filter binding assay. Michaelis-Menten plots for: F) CBP-HATwt; G) CBP-583 
HATmutant-loop. Reactions contained 0nM (green) or 10nM (orange) eRNA-Mdm2. Concentrations of 584 
CBP-HAT domain and Acetyl-CoA were 10nM and 100uM respectively. H3-1-21 peptide from 0-585 
200uM (n=4). Derived kinetic parameters for Km and Kcat in Figure S5K.  586 
H-I) Specificity constant (Kcat/Km(H3-1-21)) for reaction with 0nM or 10nM eRNA-Mdm2. H) CBP-587 
HATwt; I) CBP-HATmutant-loop.  588 
J) Mechanism for stimulation of CBP-HAT activity by RNA binding.  589 
 590 
Figure 6: Localized eRNA binding can stimulate acetyltransferase activity of CBP in vivo 591 
A) UCSC genome browser of YY1 enhancer and promoter regions. Colours as in Figure 2B. 592 
B-C) Depletion of PAR-CLIP eRNA using antisense olignucleotide (ASO) targeting: B) eRNA-593 
YY1antisense (purple); and C) eRNA-Ccnd1sense (blue); GFP-control (green). RT-qPCR shows fold-594 
change in eRNA and associated mRNA at targeted gene (top) or non-targeted control gene 595 
(bottom). Error bars represent mean +/- s.e.m; n=4. 596 
D-F) ChIP-qPCR at enhancer and promoter regions following ASO depletion of eRNA-YY1 (purple) 597 
or GFP-control (green). Foldchange (IP/H3) for: D) H3K27ac; E) H3K18ac and F) CBP (IP/Input)  598 
at YY1 and non-targeted control gene Ccnd1 (bottom). Error bars represent mean +/- s.e.m; n=4. 599 
G-I) ChIP-qPCR at enhancer and promoter regions following ASO depletion of eRNA-Ccnd1 (blue) 600 
or GFP-control (green). Foldchange (IP/H3) for: G) H3K27ac; H) H3K18ac and I) CBP (IP/Input) at 601 
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Ccnd1 and non-targeted control gene YY1 (bottom). Error bars represent mean +/- s.e.m; n=4. P-602 
values from two-tailed 6WXGHQW¶V t-test: *P< 0.05; **P< 0.01; ***P< 0.001. 603 
 604 
Figure 7:  Model for RNA stimulation of CBP HAT activity during enhancer activation.  605 
i) At inactive enhancers, CBP activity is limited by the activation loop, which occupies the active 606 
site. 607 
ii) During activation, recruitment of PolII by bound TFs PolII results in eRNA transcription. 608 
iii) eRNAs bind to the CBP HAT domain RBR, displacing the activation loop, stimulating the HAT 609 
activity of CBP and increasing H3K27ac at the enhancer and associated promoter. 610 
 611 
 612 
 613 
 614 
  615 
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Supplementary information 1 
 2 
Figure S1, related to Figure 1 3 
A) Whole western blot view of Figure 1A  4 
B) Whole autoradiography and western blot view of Figure 1C. CBP PAR-CLIP signal required 4-5 
SU. 6 
C) Western blot for CBP. Input was not 32-P labeled.  7 
D-E) Example replicates of Figure 1C quantified in Figure 1D, CBP PAR-CLIP required 4-SU: Top, 8 
Autoradiography; Bottom, western blot for CBP on PAR-CLIP membrane. Input was not 32-P 9 
labeled, but resolved and transferred to the same membrane.  10 
F-G) Whole autoradiography (F) and western blot (G) view of Figure 1E, CBP PAR-CLIP signal 11 
was sensitive to increasing RNAse concentrations. 1x RNAse cocktail contained: RNAse A 12 
(0.01mU/ul) + RNase T1 (0.4mU/ul).  13 
H) Example replicate autoradiography of Figure 1E, quantified in Figure 1F.  14 
 15 
 16 
 17 
Figure S2, related to Figure 2 18 
A) Autoradiography of 2nd biological replicate of CBP PAR-CLIP and nls-GFP (nGFP) and yeast 19 
Gal4 DNA binding domain (Gal4-DBD) background control membranes. Dashed box shows 20 
regions of membrane excised for library preparation. 21 
B) Correlation of PAR-CLIP reads from individual replicates 1 and 2 over CBP enriched RNAs 22 
called from replicate 1 (5926) and 2 (5322). Correlation of reads from replicate 1 and 2 over 23 
common peaks that were called independently in both replicates (3229) are highlighted in red. 24 
C) Distribution of sizes of CBP-RNA regions following assignment of statistically enriched RNAs 25 
with PARalyzer v1.1.  26 
D-G) Intersection of CBP-RNAs with background control RNAs: D) Gal4-DBD control 27 
intersecting nGFP control; E) CBP enriched RNA intersecting Gal4-DBD control; F) CBP enriched 28 
RNA intersecting nGFP control; G) CBP enriched RNA intersecting Gal4-DBD and nGFP control 29 
RNAs. 30 
H) Immunoprecipitation of CBP under Native RNA-IP conditions +/- treatment with 1mg/ml RNase 31 
A; WB for Mediator (Med-1 subunit) or NELF (NELF-e subunit). 32 
I) Immunoprecipitation of CBP under PAR-CLIP conditions; WB for Mediator (Med-1 subunit) or 33 
NELF (NELF-e subunit). 34 
J) Comparison of Mediator (GSM560353 (Kagey et al., 2010), left panel) and NELFb (GSE24113 35 
(Sun et al., 2011), right panel) read density over CBP-RNAs and enriched control RNAs. CBP 36 
peaks were randomly downsampled to match the size of the background dataset (5581). 37 
K-L) Enrichment of reads at CBP-RNAs sorted by genome regions from Figure 2D; L) CBP-RNA 38 
(PAR-CLIP) signal; M) Nascent RNA transcription (GROseq) signal (Promoter = 1kb upstream of 39 
TSS). 40 
M) Read density of total RNAseq datasets (GSM687308, right panel; GSM1100747, left panel) at 41 
CBP-RNAs. 42 
N-O) Comparison of nascent transcription (GROseq) and total RNAseq at CBP-RNAs; N) 43 
Enrichment of total RNAseq reads at CBP-RNAs. CBP-RNAs were grouped into deciles based on 44 
GROseq signal (10th decile = most enriched for GROseq reads). Boxplot shows total RNAseq 45 
reads (GSM1100747); O) Enrichment of GROseq signal at CBP-RNAs. CBP-RNAs were grouped 46 
into deciles based total RNAseq signal (10th decile = most enriched for total RNAseq reads). 47 
Boxplot shows total GROseq reads. 48 
P) Comparison of GROseq and total RNAseq (GSM1100747) enrichment at CBP-RNAs sorted by 49 
genome regions from Figure 2D. P-values from Mann-Whitney U-test. 50 
6XSSOHPHQWDO,QIRUPDWLRQ
Q) Spearman correlation co-efficient between PAR-CLIP and CBP ChIPseq reads over 1kb 51 
intersecting bound RNA regions at increasing peak-to-peak distances. Plot shows correlation for 52 
CBP bound RNAs (purple), Gal4-DBD (orange) and nGFP (green) background control bound 53 
RNAs. Grey dashed line highlights a 3.5kb peak-peak distance. 54 
 55 
 56 
Figure S3, related to Figure 3  57 
A-C) Comparison of read density (RPM) over enriched RNA regions <3.5kb from nearest CBP 58 
peak and >3.5kb from nearest CBP peak; A) CBP PAR-CLIP; B) CBP ChIPseq; C) GROseq.  P-59 
values from Mann-Whitney U-test. 60 
D) Histogram showing distance from RNA bound CBP peaks to nearest TSS. Peaks were divided 61 
into Promoter (TSS-1kb), Exon and Distal (intronic/intergenic) sub groups.  62 
E) Comparison of CBP signal at RNA-bound CBP peaks (<3.5kb) in Promoter, Exon and Distal 63 
groups. CBP peaks were sorted into deciles based on PAR-CLIP enrichment. Boxplots show 64 
enrichment for CBP ChIPseq reads at each decile (10th decile = most enriched for total PAR-CLIP 65 
reads). 66 
F) Comparison of PAR-CLIP signal at RNA-bound CBP peaks (<3.5kb) in Promoter, Exon and 67 
Distal groups. CBP peaks were sorted into deciles based on CBP enrichment. Boxplots show 68 
enrichment for PAR-CLIP reads at the top five deciles for CBP signal (10th decile = most enriched 69 
for total CBP ChIPseq reads). 70 
G) Comparison of PAR-CLIP signal at RNA-bound CBP peaks (<3.5kb) in Promoter, Exon and 71 
Distal groups. CBP peaks were sorted into deciles based on GROseq enrichment. Boxplots show 72 
enrichment for PAR-CLIP reads at the top five deciles for GROseq signal (10th decile = most 73 
enriched for total GROseq reads). 74 
H-M) Comparison of RNA-CBP peaks in Promoter, Exon and Distal subgroups. Profiles show 50bp 75 
bins over 5kb windows centered on the CBP peak and were normalized by number of peaks in 76 
each genome region subgroup; Promoter (green), Exon (orange), Distal (purple). Grey boxes show 77 
the 1kb window used for quantification in box-plots; H) Read density profiles of CBP reads; I) 78 
Quantification of CBP read density; J) Read density profiles of GROseq reads; K) Quantification of 79 
GROseq read density; L) Read density profiles of PAR-CLIP reads; M) Quantification of PAR-CLIP 80 
read density. All reads were normalized per million mapped reads (RPM). P-values from Mann-81 
Whitney U-test. 82 
N) Boxplot shows H3K27ac reads over RNA bound CBP peaks (green) or non-RNA bound CBP 83 
peaks (orange). P-values from Mann-Whitney U-test. non-RNA bound CBP peaks were randomly 84 
downsampled to match CBP-eRNA peaks (976). 85 
O) GROseq read density profiles (RPM) comparing RNA bound CBP peaks (green) or non-RNA 86 
bound CBP peaks (orange). non-RNA bound CBP peaks were randomly downsampled to match 87 
CBP-eRNA peaks (976). 88 
P-R) Venn diagrams showing overlap between: P) RNA bound CBP peaks and H3K4me1; Q) RNA 89 
bound CBP peaks and H3K27ac; R) All CBP peaks with H3K4me1 peaks and H3K27ac peaks. 90 
S) GO analysis (DAVID, (Huang et al., 2009)) of nearest genes to PAR-CLIP CBP peaks. (FDR <1, 91 
sorted by FDR). 92 
T) Comparison of CBP-eRNA associated genes with genes not associated with CBP-eRNA. 93 
Control population was downsized to match the 1146 genes proximal to CBP-eRNA (Gene 94 
expression microarray data from GSE54452, (Kasper et al., 2014)).P-values from Mann-Whitney 95 
U-test. 96 
U) RT-qPCR data showing fold change in CBP mRNA following infection with control adenoviral 97 
GFP (Adv-GFP, green) or knockdown with Adenoviral Cre (Adv-Cre, purple). Error bars represent 98 
mean +/- s.e.m; n=4; P-values from two-tailed 6WXGHQW¶V t-test. 99 
 100 
 101 
 102 
Figure S4, related to Figure 4  103 
A) RNA binding prediction (BindN, (Wang and Brown, 2006)) for CBP-HAT domain. Predictions for 104 
non-binding residues (green) and binding residues (red) are indicated. Residues forming the 105 
activation loop and residues 1559-1608 deleted or mutated to prevent RNA binding are 106 
highlighted.  107 
B) Purification of flag-tagged recombinant CBP from Sf9 cells (Left panel) and GST tagged CBP-108 
HAT domain from E.coli (Right panel). Both gels were stained with Coomassie. 109 
C-D) Replicate gel images of Figure 4B-C; In vitro pull down of C) eRNA-Klf6s and D) eRNA-110 
Med13ls using flag-tagged CBP. s=sense, as=antisense strand RNA. 111 
E) In vitro pull down of eRNA-Klf6 using GST-tagged CBP HAT domain constructs (see also Figure 112 
4C). RNA fraction stained with SYBR gold is shown in top panel; protein fractions stained with 113 
coomassie are shown in bottom panel. 114 
F) In vitro pull down of diverse RNA sequences using CBP-HATwt. eRNA sequences eRNA-Tet2s, 115 
eRNA-Klf4s, eRNA-Klf6s (left); lncRNA sequences HOTAIR1-300, Gas5, Meg3 (middle); exonic 116 
RNA sequences (ID-1 (exon1), Bbs2 (exon-1), Klf2 (exon-2) (right). All RNAs were resolved using 117 
6% TBE Urea gels, apart from Meg3 (resolved using denaturing agarose formaldehyde gel) and 118 
stained using SYBR Gold. 119 
G) Quantification of RNA-pulldown data in Figure S4F. n=3. 120 
H) Binding curves showing eRNA binding to CBP-HATwt. 121 
I) GST CBP-HAT domain constructs used in EMSAs showing CBP-HATwt, CBP-HATdelta-loop and 122 
CBP-HATmutant loop constructs. Constructs were designed with reference to predicted RNA binding 123 
residues (Figure S4A) and residues deleted in available X-ray crystallographic structures of the 124 
p300 HAT domain. In the mutant loop sequence, mutated residues are highlighted in lower case. 125 
J) RNA EMSA showing requirement for de-acetylation for RNA binding. GST-CBP-HATwt was 126 
expressed without co-expressing ySir2 and purified (CBP-HATac). 2nM eRNA-YY1 was titrated with 127 
0-10000nM CBP-HATac. 128 
K) RNA EMSA using CBP-HATmutant-loop. eRNA-Ccnd1 was titrated with stated concentrations of 129 
CBP-HATmutant loop. (*) CBP-HATwt (2000nM). 130 
L) Western blot for immunoprecipitated GFP-CBP (control for Figure 4M). 131 
M) Additional eRNAs (i-iv) and replicated gel images (v-x): RNA EMSA of eRNA probes using 132 
CBP-HATwt (0-10000nM); i) eRNA-YY1s; ii) eRNA-Klf6s; iii) eRNA-Ccnd1s; iv) Competition binding 133 
RNA EMSAs. Binding of 2nM 32-P radiolabelled eRNA-YY1 to CBP-HATwt (2000nM) was competed 134 
with 0-20nM un-labelled eRNA-YY1; v-vi) two replicates of eRNA-Mdm2 with CBP-HATwt (Figure 135 
4G); vii) eRNA-Med13l titration with CBP-HATwt (Figure 4H); viii) Binding of 2nM 32-P radiolabelled 136 
eRNA-Mdm2 to CBP-HATwt (2000nM) was competed with 1nM, 10nM and 20nM un-labeled eRNA-137 
Mdm2 (RNA), dsDNA or ssDNA with the same sequence; ix) RNA EMSA using CBP-HATdelta-loop. 138 
eRNA-Med13l was titrated with 0-10,000nM CBP-HATdelta-loop. (*) CBP-HATwt (2000nM); x) RNA 139 
EMSA using CBP-HATmutant-loop. eRNA-YY1 was titrated with 0-8000nM CBP-HATmutant loop. (*) CBP-140 
HATwt (2000nM). 141 
N) Whole gel images of RNA EMSA experiments in main and supplementary Figures. Numbers for 142 
the original Figures are indicated. P-values from two-tailed 6WXGHQW¶V t-test: *P< 0.05; **P< 0.01; 143 
***P< 0.001. 144 
 145 
 146 
 147 
Figure S5, related to Figure 5 148 
A) Schematic of filter binding HAT assay.  149 
B) In vitro pull-down of RNA sequences using CBP-HATwt. lncRNA HOTAIR1-300, exonic RNA (ID-1 150 
(exon1) and lncRNA Meg3. All RNAs were resolved using 6% TBE Urea gels, apart from Meg3 151 
(resolved using denaturing agarose formaldehyde gel) and stained using SYBR Gold (same 152 
experiment as Figure S4F). 153 
C) RNA dose curve filter binding assays: RNA dependent stimulation of CBP acetyltransferase 154 
activity. 5nM CBP-HATwt was titrated with 0-40nM RNA (lncRNA HOTAIR1-300, exonic RNA (ID-1 155 
(exon1) and lncRNA Meg3). Data shows fold change in rate of Acetyl-CoA incorporation 156 
(Vmax)/Concentration enzyme ([E], (s-1)) from 0nM RNA. Shaded regions represent mean +/- s.e.m 157 
(RNA n=3).  158 
D) Native PAGE showing DNA binding to reconstituted nucleosomes (top panel). Coomassie 159 
staining showing individual histones (bottom panel). 160 
E-G) Western blot HAT assay using recombinant nucleosome substrate. 1nM CBP-HATwt was 161 
titrated with 0-10nM E) eRNA-Mdm2s; F) eRNA-Ccnd1s; G) lncRNA HOTAIR1-300. The reaction was 162 
resolved by SDS-PAGE and probed for H3K27ac, H4K5ac and H3/H4 by western blot. Coomassie 163 
staining (bottom panel) shows individual histones. 164 
H) Western blot HAT assay. 1nM CBP-HATwt was titrated with 0-10nM eRNA-Mdm2 (top), eRNA-165 
PAPPA (middle) (Melo et al., 2013) or long noncoding RNA HOTAIR (bottom) (Kaneko et al., 166 
2013). Reaction was resolved by SDS-PAGE and probed for H3K27ac by western blot. Reactions 167 
contained 20uM purified recombinant H3.1 and 200uM Acetyl CoA.  168 
I) Quantification of Western blot HAT assays in Figure 5C and Figure S5B. Densitometry was 169 
determined in FIJI. For quantified Western blots, n=4). 170 
J) Western blot HAT assay: human MOF (hMOF). 1nM hMOF HAT domain was titrated with 0-171 
10nM eRNA-Mdm2. Reaction was resolved by SDS-PAGE and probed for H3K27ac by western 172 
blot. (hMOF was a kind gift of Ronen Marmorstein). Reactions contained 20uM purified 173 
recombinant H4 and 200uM Acetyl CoA. 174 
K) Kinetic parameters derived from steady state HAT assays. All analysis was carried out using nls 175 
regression in R. 176 
L) RNA integrity was checked before and after each HAT assay (Example control gel of eRNA-177 
Mdm2 from steady state HAT assays). Control reactions contained 200uM unlabeled Acetyl-CoA; 178 
RNA was extracted with Trizol and resolved on a denaturing 6% TBE urea gel stained with SYBR 179 
gold.   180 
 181 
 182 
Figure S6, related to Figure 6 183 
A-C) UCSC genome browser view of GROseq signal (+ strand purple, - strand grey) and CBP-184 
RNAs (orange bars) at enhancer and promoter regions for: A) YY1; B) Ccnd1; C) Tet2. 185 
D) ChIP-qPCR for H3K27ac (left) and H3K18ac (right) at enhancer and promoter regions following 186 
knockdown of CBP and p300. CBP/p300 flox/flox MEFs were infected with control adenoviral GFP 187 
(Adv-GFP, Green) or adenoviral Cre (Adv-Cre, purple/blue/orange). Data shows foldchange in 188 
IP/H3. Error bars represent mean +/- s.e.m; n=3. 189 
E) ASO mediated depletion of PAR-CLIP eRNA. RT-qPCR data showing foldchange in expression 190 
of eRNA and associated mRNA following transfection of ASO targeting eRNA-YY1antisense (purple), 191 
eRNA-Ccnd1sense (blue), eRNA-Tet2sense (orange) or GFP-control (green). Depletion efficiency was 192 
determined from expression of eRNA and mRNA at YY1 (top), Ccnd1 (middle) or Tet2 (bottom). 193 
Error bars represent mean +/- s.e.m; n=4. 194 
F-G) ChIP-qPCR at enhancer and promoter regions following transfection of ASO targeting eRNA-195 
YY1 (purple) or GFP-control (green) showing foldchange in IP/H3 for: F) H3K27ac and G) 196 
H3K18ac at targeted gene and non-targeted control gene Tet2 (control, bottom). Error bars 197 
represent mean +/- s.e.m; n=4; P-values from two-tailed 6WXGHQW¶V t-test. (Data is from the same 198 
experiment as Figure 6F-H) 199 
H-I) ChIP-qPCR at enhancer and promoter regions following transfection of ASO targeting eRNA-200 
Tet2 (orange) or GFP-control (green) showing foldchange in IP/H3 for: H) H3K27ac and I) 201 
H3K18ac at targeted gene Tet2 and non-targeted control gene YY1 (bottom). Error bars represent 202 
mean +/- s.e.m; n=4; P-values from two-tailed 6WXGHQW¶V t-test. 203 
J) CBP ChIP-qPCR at targeted gene Tet2 and non-targeted control gene YY1. Data shows 204 
foldchange in CBP IP/Input. Error bars represent mean +/- s.e.m; n=4; P-values from two-tailed 205 
6WXGHQW¶V t-test: *P< 0.05; **P< 0.01; ***P< 0.001. 206 
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